Prothena | PRTA - Capitale Ordinario





Capitale Ordinario Cambiamento Data
Acadia Pharmaceuticals USD 172.31M 174K 2026-09
Agios Pharmaceuticals USD 59.6M 264K 2026-06
Akebia Therapeutics USD 265.42M 199K 2025-12
ALKERMES USD 168.03M 489K 2026-09
Alnylam Pharmaceuticals USD 133.88M 141K 2026-09
Amgen USD 541M 0 2026-09
Biogen USD 146.7M 200K 2025-09
BioMarin Pharmaceutical USD 193.54M 267K 2026-06
Exelixis USD 244.68M 4.21M 2026-09
Immunic USD 120.38M 21.73M 2025-12
Incyte USD 200.98M 1.03M 2026-06
Ionis Pharmaceuticals USD 165.64M 265K 2026-06
MacroGenics USD 63.65M 86K 2026-06
Nektar Therapeutics USD 29.47M 9.09M 2026-03
Neurocrine Biosciences USD 101.3M 750K 2026-09
Prothena USD 51.74M 1.33M 2026-06
Regeneron Pharmaceuticals USD 105M 300K 2026-03
Ultragenyx Pharmaceutical USD 98.6M 300K 2026-06
Vertex Pharmaceuticals USD 253.5M 200K 2026-09